Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Controlled Phase 2 Clinical Trial of JPH203 in Patients With Advanced Biliary Tract Cancers

Next Previous
Trial Profile

Randomized Controlled Phase 2 Clinical Trial of JPH203 in Patients With Advanced Biliary Tract Cancers

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nanvuranlat (Primary)
  • Indications Adenocarcinoma; Biliary cancer; Carcinoma; Cholangiocarcinoma; Gallbladder cancer; Periampullary cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms JPH203-SBECD-P2
  • Sponsors J-Pharma

    • Most Recent Events

    • 20 Jan 2024 Results of ad-hoc analysis, classifying BTC patients by NAT2 phenotype , analyzing clinical efficacy and safety in the NAT2 NR population, presented at the 2024 Gastrointestinal Cancers Symposium
    • 06 Jun 2023 Results of subgroup analysis assessing effect of level of expression of LAT1 on nanvuranlat efficacy presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
    • 21 Jan 2023 Primary endpoint (Progression Free Survival (PFS) by blinded independent central review) has been met as per results presented at the 2023 Gastrointestinal Cancers Symposium.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top